carbetocin + oxytocin

The entry **b-Shahid Beheshti University of Medical Sciences-postpartum hemorrhage** refers to a clinical research context, specifically a Phase 2 trial conducted by Shahid Beheshti University of Medical Sciences, comparing the efficacy of **carbetocin** and **oxytocin** for the prevention of postpartum hemorrhage (PPH) in women undergoing cesarean section. Carbetocin is a synthetic, long-acting analogue of the peptide hormone oxytocin. Both agents act as agonists at the oxytocin receptor (OXTR) in the uterine myometrium, stimulating contractions that compress intra-myometrial blood vessels to reduce blood loss after delivery. While oxytocin is the standard of care typically administered as a continuous intravenous infusion, carbetocin is designed with a longer half-life, allowing for a single-dose administration. The trial evaluates whether carbetocin's pharmacokinetic profile offers superior clinical outcomes or improved convenience in the management of PPH compared to standard oxytocin protocols.

Other names

OxytocinCarbetocin